US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

IPOs and Secondary Offerings

Equity Capital Markets

Agomab Therapeutics / Equity Capital Markets

<ul>
<li>Agomab Therapeutics (AGMB US) targets a February 6 IPO, backed by Pfizer with a valuation of up to $829m.</li>
<li>Lead asset ontunisertib addresses fibrostenosing Crohn’s disease, a large underserved market, supported by a differentiated, GI-restricted ALK5 inhibition strategy.</li>
<li>A blue-chip investor base and strong underwriting syndicate support an attractive near-term risk-reward profile, though institutional and sector-dedicated order flow remains a key variable.</li>
</ul>


Agomab Therapeutics (AGMB US) targets a February 6 IPO, backed by Pfizer with a valuation of up to $829m.
Lead asset ontunisertib addresses fibrostenosing Crohn’s disease, a large underserved market, supported by a differentiated, GI-restricted ALK5 inhibition strategy.
A blue-chip investor base and strong underwriting syndicate support an attractive near-term risk-reward profile, though institutional and sector-dedicated order flow remains a key variable.


아고mAb 테라퓨틱스 NV(AGMB): 벨기에 기반 바이오테크 기업, 강력한 제약회사 지원을 등에 업고 IPO 추진